Repeated Intraperitoneal 𝛼-Radioimmunotherapy of Ovarian Cancer in Mice

Table 1

Study groups and number of mice with macroscopic and microscopic tumors and ascites.

Group	n	Treatment	Number of treatments	Macroscopic tumors	Microscopic tumors	Ascites	TFF^∗
1	18	400^†kBq ^211At-MX35 F(ab^)2 in PBS^‡	1	11/18	15/18	15/18	0.17
2	18	400^†kBq ^211At-MX35 F(ab^)2 in PBS^‡	2	16/18	16/18	8/18	0.11
3	18	400^†kBq ^211At-MX35 F(ab^)2 in PBS^‡	3	11/18	11/18	5/18	0.39
4	18	400^†kBq ^211At-MX35 F(ab^)2 in PBS^‡	4	10/18	10/18	1/18	0.44
5	18	400^†kBq ^211At-MX35 F(ab^)2 in PBS^‡	5	10/18	10/18	0/18	0.44
6	18	400^†kBq ^211At-MX35 F(ab^)2 in PBS^‡	6	6/18	6/18	0/18	0.67
7	12	MX35 F(ab^)2 in PBS	1	12/12	12/12	10/12	0

^∗TFF∶ tumor-free fraction (i.e., fraction of animals with no macro- and microscopic tumors and no ascites). Injected activities were ^†400± 14 kBq (mean ± SEM). ^‡PBS∶ phosphate-buffered saline. The presence of macroscopic tumors and ascites was assesed by careful ocular inspection during dissection 2 mo after the last administration of the radioimmunocomplex. Microscopic tumor growth was assessed by conventional histopathology. Judgements were blinded from treatment information.